United Immunity, Japan, challenges conquest of intractable solid cancer where conventional therapies are not effective for, by developing novel combination immunotherapies utilizing its potent anti-tumor T cell activating nano-immunotherapy “T-ignite”. The same technology is being used for the development of a next generation delta strain-reactive SARS-CoV-2 vaccine.
